Tranzyme to explore strategic options
Feb 8 (Reuters) - Drugmaker Tranzyme Inc said it will explore strategic options, including a sale, less than two months after it stopped the second mid-stage trial of its drug for stomach paralysis.
The company retained Stifel as its financial adviser for the strategic review process, and said it has not made a decision to pursue any specific transaction.
Tranzyme went public in April 2011 at $4 per share and has a market value of $15 million. It has two other products in early testing.
Tranzyme shares closed at 56 cents on Thursday on the Nasdaq.
- Tesla says in talks with BMW over car batteries, parts
- Exclusive: China ready to cut rates again on fears of deflation - sources
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
- China building South China Sea island big enough for airstrip: report
- Suicide bomber kills 45 at volleyball match in Afghanistan
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video